Observer Blinded, Randomised Study to Investigate Safety, Tolerability and Long-term Immunogenicity of Different Dose Regimens and Formulations of MV-CHIK in Healthy Volunteers
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 11 Jul 2019
Price : $35 *
At a glance
- Drugs Chikungunya virus vaccine (Primary)
- Indications Chikungunya virus infections
- Focus Pharmacodynamics
- Sponsors Themis Bioscience
- 08 Jul 2019 Status changed from recruiting to active, no longer recruiting.
- 28 Jan 2019 Planned primary completion date changed from 10 Dec 2018 to 10 Oct 2019.
- 10 Dec 2018 Status changed from not yet recruiting to recruiting.